<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377999</url>
  </required_header>
  <id_info>
    <org_study_id>EXP-1167</org_study_id>
    <nct_id>NCT02377999</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts</brief_title>
  <official_title>Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory open label, single treatment trial of anogenital warts with Picato® repeated
      up to 2 times with two weeks intervals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the present trial is to explore the safety, tolerability and efficacy when
      treating GW with Picato® 0.05% gel. The primary outcome measures will be related to safety
      and tolerability and consists of severity of any local reactions in the treated area;
      treatment-related adverse events (AEs) and serious AEs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of incidence and severity of Local Skin Reactions (LSR)</measure>
    <time_frame>Measured two weeks after every treatment and final measurement 2 weeks after last treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Anogenital Warts</condition>
  <arm_group>
    <arm_group_label>Treatment of genetial warts with Picato</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Picato</intervention_name>
    <arm_group_label>Treatment of genetial warts with Picato</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. A clinical diagnosis of external anogenital/perianal warts with at least 2 warts
             and no more than 20 warts located in one or more of the following anatomic locations:

               1. In both sexes: inguinal, perineal, and perianal areas

               2. In men: penis shaft, scrotum, glans penis and foreskin

               3. In women: on the vulva

          -  2. Subjects has a total wart areas of at least 10 mm2, but not more than 500 mm2

          -  3. Female subjects of childbearing potential must be confirmed not pregnant by a
             negative urine pregnancy test prior to trial treatment

        Exclusion Criteria:

          -  1. Subject has received any topical and/or destructive treatments for external
             anogenital warts within 4 weeks (within 12 months for imiquimod and within 12 weeks
             for sinecatechins) prior to enrolment

          -  2. Subject suffer from any of the following conditions:

               1. Known human immunodeficiency virus (HIV) infection

               2. An outbreak of herpes genitalis in the wart areas within 4 weeks prior to
                  enrolment

               3. Has internal (rectal urethral, vaginal/cervical) warts that require or are
                  undergoing treatment

               4. Has a dermatological disease (e.g. psoriasis) or skin condition in the wart areas

          -  3. Subjects using systemic virostatic compounds or immunosuppressive medication within
             30 days prior to enrollment

          -  4. Prior quadrivalent HPV vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merete Hædersdal, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

